Sudo Biosciences

About Sudo Biosciences

Sudo Biosciences is a biopharmaceutical company dedicated to designing and developing novel medicines to transform patients' lives. Their focus is on targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, a key mediator in cytokine signaling pathways linked to immune-mediated inflammatory conditions.

Products & Services

Brain-Penetrant TYK2 Inhibitor (SUDO-550):A potential first- and best-in-class candidate for treating multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation.

Topical TYK2 Inhibitor:A potential first- and best-in-class candidate for immune-mediated dermatologic diseases.

Specialties

TYK2 Inhibitors Immune-Mediated Inflammatory Diseases Neurodegenerative Diseases Dermatologic Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 147000000 MR: - FA: 147 million FAN: 147000000	D: 2024-02-13 FD: 2024-02-13	11 investors
2	RT: Series B T: - FT: Series B	A: 116000000 MR: - FA: $116M FAN: 116000000	D: 2023-12-20 FD: 2023-12-20	8 investors

Series B Latest

2024-02-13

$147.0M

11 investors (Pro only)

Series B 2023-12-20

$116.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Scott Byrd

Chief Executive Officer

I

Ian W. Mills

Chief Medical Officer

G

Gordon McMurray

Chief Development Officer

I

Imran Babar

Chief Business & Financial Officer

A

Anjali Pandey

SVP, Medicinal Chemistry

D

David Hennings

Vice President CMC

View 8 more team members with Pro

Unlock Full Team Directory

Recent News